Tobin Schilke is CFO at Revance Therapeutics, Inc. (RVNC). They have made 10 open-market trades across 2 companies since 2017, most recently 2026-08-20.
CIK 0001678984
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CRNX | SELL · 10b5-1 | 2026-03-03 | 2026-03-04 | $39.67 | $266K | -4.7% | -3.6% | -16.5% |
| RVNC | SELL | 2024-03-18 | 2024-03-19 | $5.04 | $47K | -3.1% | -22.3% | -42.6% |
| RVNC | SELL · 10b5-1 | 2023-07-03 | 2023-07-05 | $25.04 | $43K | -8.4% | -6.5% | -57.0% |
| RVNC | SELL · 10b5-1 | 2023-06-01 | 2023-06-05 | $30.61 | $181K | -7.1% | -20.0% | -43.4% |
| RVNC | SELL | 2023-05-15 | 2023-05-16 | $34.55 | $1.5M | -8.7% | -14.0% | -41.7% |
| RVNC | SELL · 10b5-1 | 2023-05-01 | 2023-05-02 | $31.70 | $203K | +5.8% | -8.6% | -29.0% |
| RVNC | SELL · 10b5-1 | 2023-04-03 | 2023-04-04 | $32.15 | $206K | -9.4% | +2.0% | -24.3% |
| RVNC | SELL | 2023-03-09 | 2023-03-09 | $31.59 | $1.2M | +7.2% | +2.9% | +5.1% |
| RVNC | SELL | 2023-03-01 | 2023-03-02 | $33.50 | $214K | -6.6% | +7.0% | -3.2% |
| RVNC | SELL | 2023-02-01 | 2023-02-02 | $34.60 | $222K | -6.1% | -4.4% | -2.6% |
| RVNC | SELL · 10b5-1 | 2023-01-20 | 2023-01-23 | $31.00 | $31K | +5.9% | -0.7% | -5.4% |
| RVNC | SELL · 10b5-1 | 2023-01-09 | 2023-01-10 | $27.16 | $101K | +19.1% | +17.1% | +11.8% |
| AKAO | SELL | 2018-06-26 | 2018-06-28 | $9.59 | $3K | -7.6% | -29.4% | -54.5% |
| AKAO | SELL | 2018-06-11 | 2018-06-13 | $11.95 | $25K | +0.5% | -34.6% | -59.9% |
| AKAO | SELL | 2018-02-21 | 2018-02-23 | $10.67 | $12K | +0.7% | +20.7% | +6.7% |
| AKAO | SELL | 2017-06-12 | 2017-06-14 | $21.53 | $44K | -0.0% | +7.2% | -29.5% |
| AKAO | SELL | 2017-01-26 | 2017-01-30 | $16.78 | $16K | +32.0% | +54.2% | +65.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.